Oncology

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Researchers found a protective effect against cancer in patients with autism spectrum disorder.

Lenvatinib with everolimus found to improve progression-free survival in RCC patients.

Top news of the day from across the health care landscape.

Subcapsular sinus macrophages may influence cancer mortality.

Blocking estrogen production by using an aromatase inhibitor stopped seizures in animal models.

Antiandrogen therapy plus radiotherapy shows promise reducing prostate cancer mortality.

Patients who receive antiandrogen therapy plus radiotherapy decrease their risk of death to 17%.

A high intake of fruit and vegetables in adolescence is linked to a reduced risk of breast cancer, but high alcohol consumption could increase the risk.

Hsp90 inhibitors could improve aggressive, resistant prostate cancer treatment.

Recent advances and updates in oncology and cancer drug development.

A repository of biopsy tissue was created from patients with leukemia and lymphoma.

More knowledge about deadly glioblastoma tumors has been discovered.

Patients taking mitoxantrone for multiple sclerosis found to have higher rates of breast and colorectal cancers and leukemia.

Patients administered mitoxantrone for multiple sclerosis carry higher rates of breast and colorectal cancers and leukemia.

Active surveillance seems to be safe in patients who are low risk, and certain patients at intermediate risk.

Testosterone therapy may actually inhibit the growth of aggressive prostate cancer.

Paclical/Apealea found to be non-inferior to current treatment for patients with epithelial ovarian cancer.

Top news of the day from across the health care landscape.

Blincyto granted priority status to treat a form of acute lymphoblastic leukemia.

Survivors of pediatric cancer observed to have similar health-related quality of life as older adults.

Personalized cancer treatments need to account for conditions such as heart or lung diseases.

New research shines light on cancer drug resistance.

Numerical simulations show the long-term success of immunotherapy is dependent on random fluctuations.

Cancer tumors are unable to grow larger than 2 millimeters unless angiogenesis is present.

Top news of the day from across the health care landscape.

Immune response that attacks tumors may significantly improve progression-free survival.

Proliferation assays are typically used to see how cancer cells respond to a drug, but this method may not be the most effective.